Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

Top 5 Infectious Disease News of the Week—April 22, 2018

APR 27, 2018 | CONTAGION® EDITORIAL STAFF

#5: New Findings on Zika in Semen May Change Recommendations on Preventing Sexual Transmission

A recent study investigating how long Zika virus lives in semen may bring changes to guidance on preventing sexual transmission of the virus, while another research team has found that post-natal Zika infection in infants may lead to brain damage and behavioral problems.

Zika virus transmission primarily occurs through bites from the Aedes species of mosquitoes, the same mosquitoes that transmit dengue and chikungunya viruses. In addition, the virus can spread through sexual transmission, and from a mother to her unborn baby during pregnancy. While many individuals who catch Zika do not experience symptoms, signs of a Zika infection can include fever, rash, headache, and joint and muscle pain, and the virus has been linked to an increase in Guillain-Barré syndrome. Pregnant women can catch Zika from a mosquito bite or from the semen of an infected partner. Since Brazil’s Zika outbreak, which began in 2015, reported associated cases of microcephaly and other birth defects, public health officials have warned pregnant women of congenital Zika syndrome.

Read more about Zika.

#4: Positive Clinical Responses Reported for VIBATIV in Obese & Elderly Patients with cSSSIs

At the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), representatives from Theravance Biopharma, Inc. presented positive new data gleaned from multiple studies involving telavancin, otherwise known as VIBATIV.

First discovered through a research program dedicated to developing new drugs in response to the growing threat of resistant bacteria and the life-threatening infections that result from them, telavancin is the only once-daily in vitro bactericidal antibiotic approved by the US Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), or complicated skin and skin structure infections (cSSSI), including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA).

Read more about VIBATIV.

Read more coverage from the 28th annual ECCMID Conference.

FEATURED
Big advances in treatment can